Activation of plasma components by leukocyte removal filters.
The technique of leukocyte filtration has been introduced into cardiac surgery to reduce leukocyte mediated reperfusion injury. When autologous whole blood (WB) is used as filtrate, it is more likely to be activated by the filter material than are banked red blood cell concentrates (RCC), because of its richness in plasma components. This study was designed to compare the activation of plasma components during leukocyte filtration from WB (n = 10) taken from the heart-lung machine, with RCC (n = 10) obtained from the blood bank. Leukocyte filters made from either cellulose acetate or polyester were used. Blood samples were taken simultaneously from the inlet and outlet of the filter after filtration of either 700 ml of WB or 350 ml of RCC. Results indicated that the complement cascade was activated, as reflected by the increase of C3a and C5a during filtration of WB by filters made from cellulose acetate. In contrast, there was no significant increase of C3a and C5a during filtration of RCC. The clotting system, indicated by fibrinopeptide A, and the fibrinolytic system, indicated by fibrinogen degradation products, were not activated during leukocyte filtration. These data suggest that it is the WB taken from the heart-lung machine rather than the RCC from the blood bank that is being activated during leukocyte filtration. Thus, careful selection of filter material is important for leukocyte filtration of autologous whole blood during cardiac surgery.
Gu
Y J
YJ
Department of Cardiopulmonary Surgery, University Hospital, Groningen, The Netherlands.
Van Oeveren
W
W
D002482:Cellulose / Q000031:analogs & derivatives; D015941:Complement Hemolytic Activity Assay; D003165:Complement System Proteins / Q000378:metabolism; D005069:Evaluation Studies as Topic; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005344:Fibrinopeptide A / Q000378:metabolism; D005374:Filtration / Q000295:instrumentation; D006355:Heart-Lung Machine / Q000009:adverse effects; D006801:Humans; D066298:In Vitro Techniques; D007937:Leukapheresis / Q000009:adverse effects / Q000295:instrumentation*; D007962:Leukocytes / Q000166:cytology*; D010949:Plasma / Q000378:metabolism*; D011091:Polyesters; D015427:Reperfusion Injury / Q000097:blood / Q000517:prevention & control
D005338:Fibrin Fibrinogen Degradation Products; D011091:Polyesters; D005344:Fibrinopeptide A; C005062:acetylcellulose; D002482:Cellulose; D003165:Complement System Proteins